|
|
News Breaks | | | | March 15, 2013 | | 08:31 EDT |  | CERS | Cerus signs INTERCEPT platelet agreements with blood component suppliers
Cerus Corporation announced today that the TILAK, University Clinics, Regional Hospital Innsbruck in Austria and ZIT GmbH Hamburg in Germany, signed one and four year purchase agreements, respectively, for the INTERCEPT Blood System for platelets. LKI is one of the largest hospitals in Austria, with its Central Institute for Blood Transfusion supplying an estimated 6,000 platelet units annually to the federal state of Tyrol. LKI is the second facility in Austria to adopt INTERCEPT for platelets. Implementation of the INTERCEPT platelet system at LKI is expected to start in March 2013. ZIT Hamburg supplies roughly 10,000 platelet units annually and is the largest in-house blood component supplier to the Asklepios Group, one of the three largest operators of private hospitals in Germany. Implementation is expected to occur upon ZIT Hamburg’s receipt of regulatory approval from the Paul-Ehrlich-Institut to produce INTERCEPT-treated platelets. | |
|
News For CERS From The Last 14 Days Check below for free stories on CERS the last two weeks. |
|
|
| May 10, 2013 | | 16:42 EDT | | CERS | Baker Bros. report 12.1% passive stake in Cerus
| |
|
|
|
|
|
|
